08071930882

Our Products

Nutraceutical/Herbal Products

Health Supplements

Irrigation/Inhalation solution

Hormonal Product

Anticancer Product

Pharma Products

Pharmaceutical Medicines

Veterinary External product

TIKS CLEAR SOAP

Bortezomib Injection

Bortezomib Injection Specification

Dosage Form
Injection

Life Span
24-36 months (see expiry on vial)

Origin of Medicine
India

Packaging Type
Vial

Brand Name
As specified on packaging

Indication
Treatment of multiple myeloma and mantle cell lymphoma

Pacakaging (Quantity Per Box)
Usually 1 or 2 vials per box

Salt Composition
Bortezomib 2 mg / 3.5 mg

Drug Type
Allopathic

Ingredients
Bortezomib

Physical Form
Liquid

Function
Anticancer / proteasome inhibitor

Recommended For
Multiple Myeloma, Mantle Cell Lymphoma

Dosage
As prescribed by physician

Dosage Guidelines
Intravenous or subcutaneous injection, follow physicians directions

Suitable For
Adults

Quantity
1 vial

Storage Instructions
Store below 25C, protect from light

HSN Code
30049099

Patient Advice
Administered by healthcare professional only

Route of Administration
IV or SC injection

International Approval
Export quality available

Marketed By
Reputed Indian pharmaceutical company

Prescription Required
Yes

Side Effects
Nausea, fatigue, thrombocytopenia, peripheral neuropathy (refer to leaflet)

Caution
For hospital use only

Appearance
Clear or colorless to pale yellow solution

Reconstitution Required
Yes, with sterile saline

Bortezomib Injection Trade Information

Minimum Order Quantity
300 Boxes

Delivery Time
30 Days

Main Export Market(s)
Asia

Main Domestic Market
All India

Certifications
WHO, GMP, ISO

About Bortezomib Injection

Product Name: Bortezomib Injection

Description:

Used in treatment for multiple myeloma.

Also employed in the treatment of patients with relapsed mantle cell lymphoma.

Composition:

Bortezomib 2 Mg and mannitol I.P. 20 mg

Strength / Packing

A vial of Bortezomib 2 mg

Precision Treatment for Cancer Care

Bortezomib Injection plays a vital role in modern oncology, providing targeted therapy for multiple myeloma and mantle cell lymphoma. As a proteasome inhibitor, it disrupts cancer cell growth and enhances treatment outcomes in adult patients. This injectable is suitable for hospital administration, ensuring optimal safety and efficacy during the regimen.

Strict Administration and Storage Guidelines

This product is for hospital use only and must be given by trained medical professionals via intravenous (IV) or subcutaneous (SC) routes. To maintain effectiveness, it should be stored below 25C and protected from light. Reconstitution is required with sterile saline, as specified in the instructions, ensuring accurate dosing and safe usage.

FAQ's of Bortezomib Injection:

Q: How is Bortezomib Injection administered to patients?

A: Bortezomib Injection is given either intravenously (IV) or subcutaneously (SC) by a qualified healthcare professional. The mode and frequency of administration depend on the physician's prescription and the specific treatment plan for the patient.

Q: What conditions is Bortezomib Injection recommended for?

A: This medication is primarily indicated for adults with multiple myeloma or mantle cell lymphoma, as directed by an oncologist or hematologist. Its dosage and regimen depend on the patient's individual needs and response to therapy.

Q: When should Bortezomib Injection be reconstituted, and how?

A: The injection must be reconstituted with sterile saline solution immediately prior to administration. This process is performed by hospital staff under sterile conditions to ensure the accuracy and safety of the prepared dose.

Q: Where should Bortezomib Injection be stored to maintain its integrity?

A: Vials should be stored in a cool environment below 25C and protected from light, as improper storage may compromise the medication's potency and safety.

Q: What are the potential side effects of using Bortezomib Injection?

A: Possible adverse effects include nausea, fatigue, low platelet count (thrombocytopenia), and peripheral neuropathy. Detailed side effect information is provided in the patient leaflet; patients are advised to report any unusual symptoms to their healthcare provider promptly.

Q: What are the benefits of using Bortezomib Injection in cancer therapy?

A: As a proteasome inhibitor, Bortezomib interferes with cancer cell growth and supports prolonged disease control in patients with multiple myeloma and mantle cell lymphoma. It is a key component in structured chemotherapy regimens designed to improve patient outcomes.

Tell us about your requirement